Lizox 400 Tablet: Each film coated tablet contains linezolid USP 400 mg.
Lizox 600 Tablet: Each film coated tablet contains linezolid USP 600 mg.
Lizox 600 IV Infusion: Each 300 ml sterile solution contains Linezolid USP 600 mg.
Linezolid is a synthetic antibacterial agent belonging to the oxazolidinones class, which has clinical utility in the treatment of infections caused by aerobic gram-positive bacteria. Linezolid inhibits bacterial protein synthesis through a mechanism of action different from that of other antibacterial agents; therefore, cross-resistance between Linezolid and other classes of antibiotics is unlikely. Linezolid binds to a site on the bacterial 23S ribosomal RNA of the 50S subunit and prevents the formation of a functional 70S initiation complex, which is an essential component of the bacterial translation process.
Linezolid is indicated for the treatment of: Nosocomial pneumonia, Community-acquired pneumonia, Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, Uncomplicated skin and skin structure infections, Vancomycin-resistant Enterococcus faecium infections.
Adults & Adolescents (≥12 years):
Pediatrics (Birth through 11 years):
Monoamine oxidase inhibitors, adrenergic and serotonergic agents have the potentiality for interaction with Linezolid.
It is contraindicated for use in patients who have known hypersensitivity to Linezolid or any of the other product components. Linezolid should not be used in patients taking any medicinal product that inhibits monoamine oxidases (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product.
Common side effects include diarrhea, vomiting, headache, nausea, anemia, eosinophilia, and taste disturbances.
Pregnancy: The combination should be used during pregnancy only if the expected benefit outweighs the potential foetal risk.
Lactation: The combination should not be used by nursing mothers. If it use is considered necessary, breast feeding should be stopped.
The safety and efficacy of Linezolid formulation given for longer than 28 days have not been evaluated in controlled clinical trials. Thrombocytopenia has been reported in patients receiving Linezolid. Platelet counts should be monitored in patients who are at an increased risk of bleeding and have pre-existing thrombocytopenia.
Store below 30 C, keep in dry place & protect from light. Keep out of reach of children.